Mesh meta-analysis of the effectiveness evaluation of angiogenesis inhibitors and poly ADP-ribose polymerase inhibitors in the treatment of recurrent ovarian cancer
10.3760/cma.j.cn431274-20241202-01786
- VernacularTitle:血管生成抑制剂和PARP抑制剂治疗复发性卵巢癌有效性评价的网状meta分析
- Author:
Qiuyuan SU
1
;
Jiajia TAN
;
Ling ZHAO
;
Yan KUANG
Author Information
1. 广西医科大学第一附属医院妇科，南宁 530021
- Publication Type:Journal Article
- Keywords:
Angiogenesis inhibitors;
Poly(ADP-ribose) polymerase inhibitors;
Ovarian neoplasms;
Neoplasm recurrence
- From:
Journal of Chinese Physician
2025;27(1):11-17
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy of angiogenesis inhibitors and poly ADP-ribose polymerase (PARP) inhibitors in the treatment of recurrent ovarian cancer using a mesh meta-system.Methods:Subject terms were used to search Pubmed, Embase, the Cochrane Library and web of science databases to collect randomized controlled trials related to angiogenesis inhibitors and PARP inhibitors in the treatment of recurrent ovarian cancer. The search time was established until January 1, 2024. Outcome measures included progression-free survival (PFS) and overall survival (OS). Bias risk assessment was performed using Revman 5.4 software and mesh meta-analysis was performed using gemtc package in R 4.3.1 software.Results:34 randomized controlled trials were included in the PFS and 26 in the OS. Olaparib ( HR=0.63, 95% CI: 0.40-0.99), rucaparib ( HR=0.48, 95% CI: 0.24-0.99), niraparib ( HR=0.49, 95% CI: 0.26-0.93), niraparib+ bevacizumab ( HR=0.17, 95% CI: 0.05-0.61), chemotherapy+ bevacizumab+ maintenance bevacizumab ( HR=0.54, 95% CI: 0.3-0.97) and chemotherapy+ bevacizumab ( HR=0.50, 95% CI: 0.31-0.81) had longer PFS than conventional platinum-based chemotherapy/chemotherapy+ placebo. Niraparib+ bevacizumab had the longest PFS of all pharmacological interventions. Chemotherapy plus bevacizumab ( HR=0.72, 95% CI: 0.57 -0.88) had a longer OS than conventional platinum-based chemotherapy/chemotherapy plus placebo. Conclusions:There is limited evidence that angiogenesis inhibitors alone (bevacizumab) or PARP inhibitors alone (niraparib, olaparib, and rucaparib) can improve PFS or OS in recurrent ovarian cancer, and that the combination of angiogenesis inhibitors and PARP inhibitors may be more beneficial in prolonging PFS or OS in recurrent ovarian cancer.
